



WHERE DO THE MIGHTY MOOSE FUNDS GO?



GROUNDBREAKING RESEARCH TO DEVELOP AN EARLY DETECTION OVARIAN CANCER TEST...

- **Most women with ovarian cancer are diagnosed in the advanced stage – 5-year survival rates average 25 – 30%.**
- **Dr. Kevin Elias and Dr. Dipanjan Chowdhury** have identified a pattern of microRNAs (molecules in the bloodstream) that are specific to ovarian cancer.
- **The research team has created a simple, inexpensive blood test that can detect these specific patterns and identify malignancies in their early, more treatable stages.**
- These tests are being offered to women with a high risk for developing ovarian cancer through a clinical trial at Brigham and Women's Hospital and Dana Farber Cancer Institute known as the **MiDe Study** (miRNA detection of cancer).
- **A near-term goal is to open this study at clinics throughout the nation and eventually the world – and to expand enrollment to the general population.**
- This simple blood test will simplify and **revolutionize cancer screening for ovarian cancer** – and a wide range of cancers including breast, pancreatic, prostate, liver, colon, endometrial, gastric, head and neck, and esophageal.
- **Looking ahead, Drs. Elias and Chowdhury are working towards creating a skin patch that will remove the need for a blood test and allow simpler, at home screening for ovarian and other cancers.**